Journal of Interdisciplinary Histopathology



e-ISSN: 2146-8362



Journal Home | Instructions for Authors | Current Issue | Online First | Previous Issues

« Previous Article
Next Article »

Review Article Open Access


Role of HPV Vaccine in the Prevention of Cervical Cancer

Saleh JA, Yusuph H, Zailani ZB.

Abstract
Background: Cervical cancer which affects relatively young women of child bearing age is considered to be the second most common cancer in women and a leading cause of cancer-related deaths in developing countries, a reflection of global health inequity. There are more than 450,000 newly diagnosed cases annually with over a quarter of million deaths recorded out of which over 80 percent are from the developing countries especially Africa, South Asia, South and Central America, and the Caribbean, with an exponential rise expected from this figure by 2020. The preventive measures available (Pap smear and HPV vaccine) aimed at reducing morbidity and mortality associated with this disease, has been shown to be very effective but difficult to implement especially in the developing countries partly due to lack of resources and mainly lack of government commitment amongst other things. This forms the basis of this review to look at the position of HPV vaccine in the prevention of cancer of the cervix.
Method: In the course of this write-up, relevant literatures were reviewed using manual library search, relevant websites and internet articles. The key words employed were: cervical cancer, human papilloma virus, pap smear and vaccination.
Results: It has been shown that, where resources permits, combining HPV vaccine in combination with pap smear screening methods especially to high risk group would greatly reduce the morbidity and mortality associated with cancer of the cervix.
Conclusion: Although there are so many essential questions still unanswered, considering the havoc caused by this preventable gynaecological malignancy and coupled with the ever increasing costs of its treatment, the advantages of using HPV vaccine in addition to routine Pap smear as a means of preventing cancer of the cervix greatly outweighs the disadvantages. However, there is the need for caution to be adhered to when it comes to large scale vaccination programs in view of the fact that sufficient evidence is still lacking on the safety of the vaccines in the long-term.

Key words: CERVICAL CANCER, HUMAN PAPILLOMA VIRUS, PAP SMEAR, VACCINATION


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Saleh JA
Articles by Yusuph H
Articles by Zailani ZB
on Google
on Google Scholar
Article Statistics
 Viewed: 2033
Downloaded: 688
Cited: 0

REFERENCES
Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24: Suppl 3:S26-S34.

http://dx.doi.org/10.1016/j.vaccine.2006.05.026

[Pubmed]   

Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88:63-73.

http://dx.doi.org/10.1038/sj.bjc.6600688

[Pubmed]    [PMC Free Fulltext]   

Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries-Key challenges and issues. N Engl J Med 2007; 356;19:1908-1910.

http://dx.doi.org/10.1056/NEJMp078053

[Pubmed]   

Lowndes CM. Vaccines for cervical cancer [Editorial Review]. Epidemiol. Infect 2006; 134: 1-12.

http://dx.doi.org/10.1017/S0950268805005728

[Pubmed]    [PMC Free Fulltext]   

Dim CC, Ekwe E, Madubuko T, Dim NR, Ezegwui HU. Improved awareness of Pap smear may not affect its use in Nigeria: a case study of female medical practitioners in Enugu, southeastern Nigeria. Trans R Soc Trop Med Hyg. 2009;103(8):852-854.

http://dx.doi.org/10.1016/j.trstmh.2009.03.020.

[Pubmed]   
Mayun AA, Nggada HA, Audu BM, Pindiga UH, Khalil MI, Musa AB. Histopathological analysis of non-squamous cell malignancies of the uterine cervix in Maiduguri, Nigeria. Afr J Med Sci 2008;37(4); 369-373.

[Pubmed]   
Ijaiya MA, Aboyeji PA, Buhari MO. Cancer of the cervix in Ilorin, Nigeria. West Afr J Med 2004;23(4); 319-322.

[Pubmed]   

Olatunji AO, Sule-Odu AO. Cancer of the cervix. Niger Postgrad Med J 2005;12(4):308-311.

[Pubmed]   

The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.

http://dx.doi.org/10.1056/NEJMoa061741

[Pubmed]   

Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369: 1861-1868.

http://dx.doi.org/10.1016/S0140-6736(07)60852-6

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-1943.

http://dx.doi.org/10.1056/NEJMoa061760

[Pubmed]   

Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-2170. [Erratum, Lancet 2007; 370: 1414].

http://dx.doi.org/10.1016/S0140-6736(07)60946-5

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-1255.

http://dx.doi.org/10.1016/S0140-6736(06)68439-0

Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24 (Suppl 3):S35-S41.

http://dx.doi.org/10.1016/j.vaccine.2006.06.015

[Pubmed]   

Charlotte JH. Human papilloma virus vaccination- reasons for caution. N Engl J Med 2008; 359:861-862.

http://dx.doi.org/10.1056/NEJMe0804638

[Pubmed]   

Weinstock H, Berman S, Cates W Jr. Sexually transmitted disease among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36:6-10.

http://dx.doi.org/10.1363/3600604

[Pubmed]   

Noah N. Controlling Communicable Disease, Open University Press, London 2006.


How to Cite this Article
Pubmed Style

JA S, H Y, ZB Z. Role of HPV Vaccine in the Prevention of Cervical Cancer. J Interdiscipl Histopathol. 2013; 1(4): 212-216. doi:10.5455/jihp.20130119122700



Web Style

JA S, H Y, ZB Z. Role of HPV Vaccine in the Prevention of Cervical Cancer. www.scopemed.org/?mno=31202 [Access: June 28, 2017]. doi:10.5455/jihp.20130119122700



AMA (American Medical Association) Style

JA S, H Y, ZB Z. Role of HPV Vaccine in the Prevention of Cervical Cancer. J Interdiscipl Histopathol. 2013; 1(4): 212-216. doi:10.5455/jihp.20130119122700



Vancouver/ICMJE Style

JA S, H Y, ZB Z. Role of HPV Vaccine in the Prevention of Cervical Cancer. J Interdiscipl Histopathol. (2013), [cited June 28, 2017]; 1(4): 212-216. doi:10.5455/jihp.20130119122700



Harvard Style

JA, S., H, Y. & ZB, Z. (2013) Role of HPV Vaccine in the Prevention of Cervical Cancer. J Interdiscipl Histopathol, 1 (4), 212-216. doi:10.5455/jihp.20130119122700



Turabian Style

JA, Saleh, Yusuph H, and Zailani ZB. 2013. Role of HPV Vaccine in the Prevention of Cervical Cancer. Journal of Interdisciplinary Histopathology, 1 (4), 212-216. doi:10.5455/jihp.20130119122700



Chicago Style

JA, Saleh, Yusuph H, and Zailani ZB. "Role of HPV Vaccine in the Prevention of Cervical Cancer." Journal of Interdisciplinary Histopathology 1 (2013), 212-216. doi:10.5455/jihp.20130119122700



MLA (The Modern Language Association) Style

JA, Saleh, Yusuph H, and Zailani ZB. "Role of HPV Vaccine in the Prevention of Cervical Cancer." Journal of Interdisciplinary Histopathology 1.4 (2013), 212-216. Print. doi:10.5455/jihp.20130119122700



APA (American Psychological Association) Style

JA, S., H, Y. & ZB, Z. (2013) Role of HPV Vaccine in the Prevention of Cervical Cancer. Journal of Interdisciplinary Histopathology, 1 (4), 212-216. doi:10.5455/jihp.20130119122700